SLC5A2 and cardiovascular disorder: We conducted a retrospective cross-sectional study of all Cochrane reviews evaluating the effects of these drugs on cardiovascular disease (CVD) management up to August 2024, summarising the evidence and calculating the lag in time between patient enrolment in trials and current decision-making (August 2024).<h4>Results</h4>We identified 57 Cochrane reviews on statins, with 9 (15.8%) meeting our criteria, and 6 reviews on SGLT-2 inhibitors, with 2 (33.3%) being eligible.